Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study by Lotte Heimans et al.
Heimans et al. Arthritis Research & Therapy 2013, 15:R173
http://arthritis-research.com/content/15/5/R173RESEARCH ARTICLE Open AccessHealth-related quality of life and functional ability
in patients with early arthritis during remission
steered treatment: results of the IMPROVED study
Lotte Heimans1*, Kirsten VC Wevers-de Boer1, KK Michel Koudijs1, Karen Visser1, Yvonne P Goekoop-Ruiterman2,
Joop B Harbers3, Gerda M Steup-Beekman4, Leroy R Lard5, Bernard AM Grillet6, Tom WJ Huizinga1
and Cornelia F Allaart1Abstract
Introduction: The aim of this study was to investigate patient reported outcomes (PROs) of functional ability and
health related quality of life (HRQoL) in patients with early (rheumatoid) arthritis during one year of remission
steered treatment.
Methods: In this study, 610 patients with early rheumatoid arthritis (RA) or undifferentiated arthritis (UA) were
treated with methotrexate (MTX) and tapered high dose of prednisone. Patients in early remission (Disease Activity
Score (DAS) <1.6 after 4 months) tapered prednisone to zero and when in persistent remission, also tapered MTX.
Patients not in early remission were randomized to either MTX + hydroxychloroquine + sulphasalazine + prednisone
(arm 1) or to MTX + adalimumab (arm 2). Every 4 months, patients filled out the Health Assessment Questionnaire
(HAQ) and the McMaster Toronto Arthritis Patient Preference Questionnaire (MACTAR), the Short Form 36 (SF-36)
and visual analogue scales (VAS). Change scores were compared between treatment groups. The association with
achieving remission was analyzed using linear mixed models.
Results: During year 1, patients who achieved early remission had the most improvement in PROs with scores
comparable to the general population. Patients in the randomization arms showed less improvement. Scores were
comparable between the arms. There was a significant association between achieving remission and scores of HAQ,
MACTAR and physical HRQoL.
Conclusions: In early arthritis, PROs of functional ability and HRQoL after one year of remission steered treatment
reach normal values in patients who achieved early remission. In patients not in early remission, who were
randomized to two strategy arms, PROs improved less, with similar scores in both treatment arms.
Trial registrations: ISRCTN11916566 and EudraCT2006-006186-16Introduction
In rheumatoid arthritis (RA), treatment with disease-
modifying antirheumatic drugs (DMARDs) is targeted at
achieving optimal suppression of disease activity. With
that treatment, clinical symptoms as well as radiological
joint damage (progression) are prevented and patient-
reported outcomes (PROs) such as pain, health-related
quality of life (HRQoL) and physical and mental well-* Correspondence: l.heimans@lumc.nl
1Department of Rheumatology, Leiden University Medical Center,
PO Box 9600, 2300 RC, Leiden, The Netherlands
Full list of author information is available at the end of the article
© 2013 Heimans et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orbeing improve [1]. Earlier studies have suggested that
the better disease activity is suppressed, the better the
outcomes regarding function and radiological joint dam-
age progression [2,3]. Achieving clinical remission would
ideally be associated with achieving PROs comparable to
those in the general population.
In the Induction therapy with Methotrexate and Pred-
nisone in Rheumatoid or Very Early arthritic Disease
(IMPROVED) study, DMARD treatment was targeted at
achieving remission. Patients with early RA were initially
treated with combination therapy comprising metho-
trexate (MTX) and prednisone. If clinical remissional Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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within 4 months, patients were randomized into two
treatment arms: either with a combination of nonbiolo-
gic DMARDs and low-dose prednisone or with MTX
and the TNF-α inhibitor adalimumab (ADA). The aim of
this subanalysis was to measure change in functional
ability and HRQoL during the first year of remission-
steered treatment to compare outcomes between the




The IMPROVED study is a multicenter, randomized,
single-blind trial comparing two combination therapies
in patients with recent-onset arthritis. Its aim is achie-
ving clinical remission, which is defined as a DAS less
than 1.6. The IMPROVED trial was designed and con-
ducted by rheumatologists in the Foundation for Ap-
plied Rheumatology Research and is registered in the
International Standard Randomised Controlled Trial
Register (ISRCTN11916566) and the European Clinical
Trials Database (EudraCT2006-006186-16).
Patients were recruited between March 2007 and
September 2010 from 12 hospitals in the western part of
The Netherlands. The medical ethics committee of each
participating center approved the study protocol (see
Acknowledgements), and all patients gave their written
informed consent to participate. Patients with RA and
patients with undifferentiated arthritis (UA) were inclu-
ded. RA was diagnosed according to the 2010 American
College of Rheumatology and European League against
Rheumatism (ACR/EULAR) classification criteria [4]
with duration of symptoms less than 2 years. UA was de-
fined as arthritis in at least one joint and one other pain-
ful joint in which no definitive diagnosis could be made,
which was considered to be early RA according to the
treating rheumatologist, regardless of symptom duration.
All patients were at least 18 years old and had a DAS of
1.6 or higher. Detailed inclusion and exclusion criteria
have been described previously [5].
All patients were initially treated for 4 months with
MTX 25 mg/wk and a tapered high dose of prednisone,
starting with 60 mg/day and tapered to 7.5 mg/day dur-
ing the course of 7 weeks. For patients in early remission
(DAS less than 1.6 after 4 months), prednisone was
tapered to 0, and, if still in remission after 8 months,
MTX was also tapered to 0. Patients not in early remis-
sion (DAS 1.6 or higher) were randomized using variable
block randomization and stratified per center to ensure
numerical equality of the two treatment groups. The
randomization sequence was obtained by computer. At
the local centers, allocation of UA and RA patients was
performed by drawing opaque envelopes from separateboxes. Patients were randomized to either a combina-
tion of either (1) MTX 25 mg/wk, hydroxychloroquine
(HCQ) 400 mg/day, sulfasalazine (SSZ) 2,000 mg/day
and prednisone 7.5 mg/day (arm 1) or (2) a combination
of ADA 40 mg/2 weeks and MTX 25 mg/wk (arm 2).
When patients did not achieve remission within 8 months,
those in arm 1 were switched to ADA+MTX and for
those in arm 2, the dosage of ADA was increased to 40
mg/wk. For patients in both arms who achieved remission
within 8 months, treatment was tapered to MTX mono-
therapy. Patients who did not achieve remission but were
not randomized were analyzed as a separate group, called
the outside protocol (OP) subgroup [6].
Outcomes
Functional ability was assessed every 4 months with the
Health Assessment Questionnaire (HAQ) [7]. The HAQ
score of the general Finnish population is 0.25 [8].
The McMaster Toronto Arthritis Patient Preference
Questionnaire (MACTAR) also measures functional
ability. Patients rank five activities in which they are
impaired because of their arthritis. Over time, improve-
ment or deterioration of these five activities can be mea-
sured. The MACTAR is sensitive to change and useful
for the detection of small differences. Compared to the
baseline score, a higher score denotes improvement and
a lower score indicates deterioration. The MACTAR
interview from Canada was translated into Dutch in col-
laboration with the author of the original MACTAR.
The translation was first used in the COBRA study of
combination therapy in rheumatoid arthritis, in which
it was validated and adjudged to be highly responsive
[9-11].
HRQoL was assessed using the 36-Item Short Form
Health Survey (SF-36), focusing on eight domains of
health: physical functioning, role limitations due to
physical or emotional functioning, bodily pain, general
health, vitality, social functioning and mental health. The
total score ranges from 0 (worst) to 100 (best). Two
summary component scores, the Mental Component
Score (MCS) and the Physical Component Score (PCS),
can be calculated from among the eight domains. These
component scores are standardized on the basis of
worldwide population norms to a mean of 50 and a
standard deviation of 10 [12,13]. The minimum clinically
important difference for assessing improvement or de-
terioration is a 5- to 10-point difference from baseline
for the subscales and from 2.5 to 5 points for the com-
ponent scores [14].
Various Visual Analogue Scales (VASs) were used, on
which patients had to indicate on a scale from 0 to 100
mm (0 means none and 100 means the worst) their rat-
ing of their global health (VASgl), pain (VASpain), disease
activity (VASda) and morning stiffness (VASms).
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All outcomes were calculated according to the intention-
to-treat principle. All mean outcomes after 4 months, 8
months and 1 year were tested between arms 1 and 2
using Student’s t-test, and we used the χ2 test to test the
difference in remission rates.
HAQ, MACTAR, MCS, PCS and VAS scores were re-
ported separately for patients who achieved early remis-
sion and those who were randomized, and the scores
were compared between the randomization arms. The
results of the study population were compared with
those in the general population, if those data were
available.
Mean score changes over time were tested between
the randomization arms using an independent Student’s
t-test. Clinically relevant improvement or deteriora-
tion in HRQoL after 1 year was assessed per treat-
ment group on the basis of the minimum clinically
important difference.
To assess the relationship between achieving remission
and the PROs PCS, MCS, HAQ and MACTAR, a linear
mixed model (with an unstructured covariance scheme)
was used. The analyses were first performed with an
interaction term for remission achievement and treat-
ment (early remission, arm 1, arm 2 and OP group)Table 1 Baseline characteristics of all patientsa
Early remission
Baseline characteristics (N = 387)
Mean age (±SD), years 52 ± 14
Females, n (%) 239 (62)
Symptom duration, weeks 17 (9 to 30)
ACPA-positive, n (%) 225 (58)
RA2010, n (%) 297 (77)
Erosive disease, n (%) 63 (16)
DAS, mean ± SD 3.0 ± 0.9
Tender joint count, median (IQR) 5 (2 to 9)
Swollen joint count, median (IQR) 5 (3 to 8)
HAQ, mean ± SD 1.0 ± 0.7
MCS, mean ± SD 51.2 ± 10.2
PCS, mean ± SD 37.6 ± 9.3
Mean MACTAR, mean ± SD 50.1 ± 4.5
Mean VASgl (±SD), mm 43 ± 24
Mean VASda activity (±SD), mm 56 ± 25
Mean VASpain (±SD), mm 50 ± 24
Mean VASms (±SD), mm 56 ± 27
aData are presented as mean ± SD, median (IQR or number (%). ACPA: anticitrullinat
Questionnaire; MACTAR: McMaster Toronto Arthritis Patient Preference Questionnai
OP group: outside protocol subgroup; PSC: Physical Component Score on the 36-Ite
2010 American College of Rheumatology and European League against Rheumatism
VASms: morning stiffness; VASpain: pain.because the different treatment strategies might influ-
ence remission achievement.
As fixed effects were entered into the model: time (study
visits at 4 months, 8 months and 1 year) and mean base-
line score of the assessed PRO. In cases of a significant
interaction term, the analyses were stratified for treatment.
The association between remission and PROs was assessed
with and without adjustment for the baseline variables
anticitrullinated protein antibody (ACPA) status (positive
or negative), sex (male or female), DAS at baseline, tender
joint count and swollen joint count which were entered in
the model as fixed effects. We used these determinants be-
cause they were identified as predictors for achieving re-
mission after the first 4 months of the study [5]. After the
initial analysis in which remission was defined as a DAS
less than 1.6, we reanalyzed the association with remission
defined according to the provisional Boolean-based remis-
sion definition published by ACR/EULAR with a 44-joint
count DAS [15]. Statistical analyses were conducted using
SPSS for Windows version 20.0 software (SPSS, Inc,
Chicago, IL, USA).
Results
In total, 610 patients were included. During the first
year, 32 patients left the trial (23 withdrew consent, 3Arm 1 Arm 2 OP group
(N = 83) (N = 78) (N = 50)
48 ± 14 51 ± 14 54 ± 14
63 (76) 64 (82) 42 (84)
22 (9 to 40) 21 (8 to 29) 18 (9 to 42)
40 (48) 36 (46) 25 (50)
66 (80) 64 (82) 40 (80)
10 (12) 13 (17) 3 (6)
3.6 ± 0.9 3.6 ± 1.0 3.6 ± 0.9
6 (3 to 10) 8 (4 to 12) 7 (3 to 13)
8 (6 to 13) 9 (6 to 13) 8 (6 to 14)
1.4 ± 0.6 1.4 ± 0.65 1.3 ± 0.7
46.1 ± 12.4 48.8 ± 11.5 46.5 ± 13.3
33.0 ± 8.8 32.9 ± 8.9 35.2 ± 8.5
47.7 ± 4.6 48.1 ± 4.6 47.7 ± 5.2
54 ± 20 54 ± 22 51 ± 22
66 ± 19 67 ± 22 66 ± 20
63 ± 19 61 ± 20 60 ± 24
69 ± 21 62 ± 25 54 ± 30
ed protein antibody; DAS: Disease Activity Score; HAQ: Health Assessment
re; MCS: Mental Component Score on the 36-Item Short Form Health Survey;
m Short Form Health Survey; RA2010: rheumatoid arthritis according to the
classification criteria [4]; VASda: disease activity; VASgl: global health;
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dropped out because of comorbidity). After 4 months,
387 achieved early remission (DAS less than 1.6). Of the
221 patients who did not achieve early remission, 161
patients were randomized: 83 patients into arm 1 (poly-
DMARDs) and 78 into arm 2 (ADA +MTX). Fifty pa-
tients did not achieve remission but were not randomized
(assigned to the OP subgroup) [6]. Patients who achieved
early remission had lower mean baseline DAS, lowerTable 2 Patient-related outcomes of all patients during 1 yea
Early remission







VASgl, mm 14 (14)
VASda, mm 12 (15)
VASpain, mm 10 (14)







VASgl, mm 20 (20)
VASda, mm 22 (23)
VASpain, mm 19 (23)







VASgl, mm 20 (21)
VASda, mm 24 (26)
VASpain, mm 21 (23)
VASms, mm 25 (26)
Remission (DAS <1.6) 263 (68)
aData are means ± SD, medians (IQR) or numbers (%) as appropriate. ACPA: anticitru
Questionnaire; MACTAR: McMaster Toronto Arthritis Patient Preference Questionnai
PSC: Physical Component Score on the 36-Item Short Form Health Survey; RA2010:
and European League against Rheumatism classification criteria; VASda: disease acti
represents the difference in mean scores and remission rates between arms 1 andvalues of all DAS components and shorter symptom
duration and included fewer females and more patients
positive for ACPA (Table 1) [5].
At the 1-year follow-up visit, we found that remission
was most often achieved by patients in the early remis-
sion group (68%). Fewer patients randomized to arm 1
had achieved remission at 1 year than patients ran-
domized to arm 2 (25% and 40%, respectively; P = 0.01)
(Table 2).r of follow-upa
Arm 1 Arm 2 OP group
(N = 83) (N = 78) P (N = 50)
2.49 (0.63) 2.57 (0.68) 0.47 2.31 (0.63)
0.86 (0.57) 0.88 (0.57) 0.77 0.73 (0.68)
52.8 (15.1) 48.9 (18.8) 0.14 51.6 (14.1)
48.8 (9.9) 50.7 (10.8) 0.26 49.8 (10.5)
39.4 (9.7) 38.1 (9.4) 0.44 42.5 (9.4)
37 (21) 39 (21) 0.61 28 (22)
42 (24) 43 (24) 0.74 32 (25)
39 (24) 38 (24) 0.79 27 (24)
40 (27) 39 (27) 0.78 32 (30)
1.97 (0.87) 2.01 (0.91) 0.77 2.02 (0.84)
0.74 (0.61) 0.81 (0.64) 0.51 0.68 (0.59)
55.8 (14.7) 54.5 (16.1) 0.60 48.9 (19.9)
46.6 (17.9) 48.7 (10.3) 0.85 48.5 (13.0)
42.8 (10.9) 42.5 (11.0) 0.26 43.7 (9.5)
33 (23) 34 (21) 0.75 30 (23)
39 (26) 33 (24) 0.20 35 (25)
35 (26) 31 (25) 0.36 32 (24)
34 (29) 37 (28) 0.51 40 (27)
2.07 (0.89) 1.77 (0.90) 0.04 2.20 (0.83)
0.87 (0.66) 0.81 (0.66) 0.60 0.77 (0.65)
59.2 (10.3) 60.4 (11.9) 0.54 59.7 (11.21)
50.5 (10.3) 50.5 (10.1) 0.97 50.4 (11.9)
39.9 (10.3) 43.0 (11.4) 0.10 42.6 (10.9)
33 (23) 27 (20) 0.10 33 (24)
42 (29) 31 (26) 0.02 34 (27)
38 (28) 28 (25) 0.02 28 (25)
41 (31) 33 (27) 0.96 39 (30)
21 (25) 32 (41) 0.01 11 (22)
llinated protein antibody; DAS: Disease Activity Score; HAQ: Health Assessment
re; MCS: Mental Component Score on the 36-Item Short Form Health Survey;
rheumatoid arthritis according to the 2010 American College of Rheumatology
vity; VASgl: global health; VASms: morning stiffness; VASpain: pain. P-value
2.
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HAQ scores in the early remission group were lower,
indicating better functional ability, than in the randomi-
zation arms, both at baseline and after 1 year (Figure 1).
Functional ability improved the most during the first 4
months in all patients (Figure 1). The mean improve-
ment in HAQ during the first year was comparable
between arms 1 and 2 (mean difference = −0.005, 95%
CI = −0.3 to 0.2). In the early remission group, the
mean HAQ score after 1 year, 0.38, was closest to the
general population mean of 0.25 (compared to mean
HAQ scores of 0.87 in arm 1 and 0.88 in arm 2)
(Figure 1 and Table 2).
Functional ability measured by the MACTAR, which is
more sensitive to change than the HAQ, improved in all
groups, together with continuous improvements in mean
DAS (Tables 1 and 2). The mean change in MACTAR in
year 1 was not significantly different between arms 1
and 2 (mean difference = −1.1, 95% CI = −5.2 to 3.1).
The outcomes of the OP group were comparable to
those in arms 1 and 2.
Health-related quality of life
At baseline in all groups, mental HRQoL measured with
the MCS was higher than physical HRQoL measured
with the PCS (Table 1 and Figure 2). Overall, the MCSFigure 1 Functional ability as measured by the Health Assessment Qu
Preference Questionnaire. Scores in the first year in the general populatio
remission group, arm 1, arm 2 and the outside protocol subgroup. MACTAat baseline was already close to the population average
of 50, and improvement during the first year was min-
imal (Table 1 and Figure 2), although clinically relevant
in the randomization arms based on the minimal clinic-
ally important difference in mean component scores of
2.5 to 5 points (improvement in arm 1 = 3.8 ±11.4, im-
provement in arm 2 = 2.8 ± 10.0). The mean improve-
ment after 1 year was not significantly different between
arms 1 and 2 (mean difference = 1.0, 95% CI = −2.8 to
4.7). The domains in which the most improvement was
seen were the roles emotional and social functioning
(Figure 3).
For the PCS, baseline scores in all groups were below
the population average of 50 (Table 1 and Figure 2). The
early remission group improved to the population aver-
age during the first 4 months of treatment and stabi-
lized, whereas the patients in the randomization arms
also improved during the first 4 months and stabilized,
but below the population average (Table 2 and Figure 2).
The mean improvement (±SD) at 1 year was clinically
relevant in all groups based on the minimal clinically
important difference of 2.5 to 5 points in the early
remission group, 11.1 (SD 11.7); arm 1, 8.0 (10.9), and
arm 2, 10.1 (12.8). The mean improvement at 1 year be-
tween patients who did versus those who did not achieve
early remission was significantly higher in patients whoestionnaire and the McMaster Toronto Arthritis Patient
n (only for Health Assessment Questionnaire (HAQ)), the early
R: McMaster Toronto Arthritis Patient Preference Questionnaire.
Figure 2 Summary components scores of health as measured by the 36-Item Short Form Health Survey. The 36-Item Short Form Health
Survey (SF-36) Mental Component Score (MCS) and Physical Component Score (PCS) can be calculated from the eight SF-36 domains (physical
functioning, role limitations due to physical functioning, bodily pain, general health, vitality, social functioning, role limitations due to emotional
functioning and mental health) [12,13]. OP: outside protocol subgroup.
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CI = −4.9 to 0.5). There was no significant difference
between arms 1 and 2 (mean difference = −2.1, 95%
CI = −6.3 to 2.1). The domains in which most im-
provement was seen were physical functioning, bodily
pain and role limitations due to physical functioning
(Figure 3). Again, MCS and PCS in the OP group
were comparable to those scores in arms 1 and 2.Visual Analogue Scale scores
Patients who achieved early remission had lower VAS
scores (indicating better outcomes) at baseline and at 1
year than patients in the randomization arms (Tables 1
and 2). Patients in arm 2 reported lower VAS scores
than patients in arm 1 at 1 year (Table 2). Only the
VASda showed more improvement at 1 year in arm 2
than in arm 1 (mean difference = 13, 95% CI = 2 to 23).
For the other VAS scores, the improvements were com-
parable between the randomization arms (mean difference
(95% CI) VASgl = 7 (−2 to 16), VASpain = 9 (−1 to 19) and
VASms = 7 (5 to 16). The OP group had results similar to
those of patients in arms 1 and 2.Association of patient-reported outcomes with remission
The analyses of the HAQ score and the PCS were strati-
fied by treatment group because there was an interaction
between treatment group and achieving remission, with
remission defined as DAS less than 1.6. The association
between HAQ and achieving remission and between
PCS and achieving remission was significant in all
groups during the first year of the study (Table 3). The
analyses for MACTAR and MCS were not stratified. In
the total study group, there was a significant association
between MACTAR and achieving remission. There was
also a significant association between MCS and achieving
remission in the total study group, but after adjustment
(for ACPA status (positive or negative), sex (male or
female), DAS at baseline and tender and swollen joint
counts at baseline), this association was no longer found
(Table 3). Results were the same when we used the ACR/
EULAR provisional remission definition (data not shown).Discussion
We assessed PROs of functional ability and HRQoL in
patients with UA and early RA who were treated with
Figure 3 The eight domains of health measured by the 36-Item Short Form Health Survey. For the eight domains measured by the
36-Item Short Form Health Survey (physical functioning, role limitations due to physical functioning, bodily pain, general health, vitality, social function-
ing, role limitations due to emotional functioning and mental health), the total score ranges from 0 (worst) to 100 (best). OP: outside protocol subgroup.
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Table 3 Association between patient-reported outcomes and remission during 1 year of follow-upa
Measurements All Early remission Arm 1 Arm 2 OP group
Crude β (95% CI)
HAQ – −0.31 (−0.36 to −0.26) −0.43 (−0.57 to −29) −0.45 (−0.58 to −0.32) 0.18 (−0.33 to −0.02)
MACTAR 7.8 (6.9 to 8.9) – – – –
PCS – 6.2 (5.1 to 7.4) 10.2 (7.5 to 12.9) 8.9 (5.8 to 12.0) 4.5 (0.6 to 8.4)
MCS 0.8 (0.01 to 1.6) – – – –
Adjusted β (95% CI)
HAQ – −0.30 (−0.35 to −0.25) −0.43 (−0.57 to −29) −0.45 (−0.58 to −0.32) 0.17 (−0.32 to −0.01)
MACTAR 8.1 (7.0 to 9.2) – – – –
PCS – 6.0 (4.9 to 7.2) 9.9 (7.1 to 12.7) 9.1 (6.1 to 12.1) 4.2 (0.2 to 8.1)
MCS 0.8 (−0.01 to 1.7) – – – –
aCI: confidence interval; HAQ: Health Assessment Questionnaire; MACTAR: McMaster Toronto Arthritis Patient Preference Questionnaire; MCS: Mental Component
Score of the 36-Item Short Form Health Survey; OP: outside protocol subgroup; PCS: Physical Component Score of the 36-Item Short Form Health Survey. Fixed
effects were entered for time (study visits at 4 months, 8 months and 1 year) and mean baseline score of the assessed PRO. The analyses were also performed
with adjustment (adjusted β) for ACPA status (positive or negative), sex (male or female), DAS at baseline and tender and swollen joint counts, and these were also
entered into the analysis as fixed variables. For HAQ score and PCS, we stratified for treatment group (early remission, arm 1, arm 2 and OP subgroup) because
there was a significant interaction between treatment group and achieving remission.
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tients who had achieved early remission at 4 months had
the best PROs at baseline and during the first year of the
study, and only in these patients did PROs reach levels
comparable to those measured in the general population.
Patients who did not achieve early remission and were
randomized to therapy with multiple DMARDs with
prednisone or a combination of MTX with ADA had
lower, and between arms comparable, PRO scores during
the first year.
At baseline, the IMPROVED study population, which
had a mean age of 52 years, scored lower on all domains
of the physical HRQoL compared to healthy individuals
in the Dutch population older than 70 years of age [12].
Therefore, it seems that the disease burden of early arth-
ritis is substantial. With treatment, the component score
for physical HRQoL showed a clinically relevant im-
provement in all groups, with the most improvement oc-
curring in the early remission group during the first 4
months. The mental HRQoL remained stable around the
population average during the first year of treatment,
which suggests that the impact of early arthritis is
mainly physical. This was also shown in previous pub-
lished studies [1,16]. However, improvement of physical
HRQoL and HAQ scores to the population average in
the first year after diagnosis in a remission-steered treat-
ment protocol was not reported earlier [1,17].
It is generally accepted that remission is the optimal
treatment target in RA. Ideally, remission would result
in patients having no radiological joint damage progres-
sion, no symptoms and no limitations; in other words,
normality, functional ability and quality of life compar-
able to that of the general population. More than DASs,
PROs show whether such improvement can be achieved
if treatment is steered at achieving remission. Thecurrent results indicate that scores comparable to those
in the general population can indeed be achieved, but
mainly in patients who were in early remission after 4
months of initial treatment. There might be a two-sided
relationship between early remission and better PRO
scores, because patients who achieved early remission
had better PRO scores at baseline than patients who did
not. This indicates that a predisposition to achieving re-
mission determines outcomes. Our results indicate that
patients with milder disease or better predisposition to
achieving remission benefit from remission-steered treat-
ment because this allows them to achieve normal levels of
functional ability and quality of life, which may have a sig-
nificant impact on their ability to work and decrease the
personal and societal costs associated with RA [18,19].
The magnitude of the association between remission and
the various PROs was actually bigger in arms 1 and 2 than
in the early remission group, which had better PROs after
1 year as well as better PROs at baseline than the patients
in arms 1 and 2. This suggests that, regardless of baseline
score, achieving remission itself is associated with PRO
improvement.
One may also argue that, without treatment, the arth-
ritis in these patients would have regressed and function
and quality of life would have been restored. However,
we previously showed that a majority of patients who
achieved remission were ACPA-positive, which makes
spontaneous remission less likely [5].
Although significantly more patients in arm 2 than in
arm 1 had achieved remission at 1 year, we found no sig-
nificant differences in improvement of functional ability,
HRQoL and VAS results between arms. Only VASda as
rated by the patient improved more in arm 2 than in
arm 1. Despite continued treatment adjustments tar-
geted at remission, remission percentages in both arms
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sibly as a consequence, functional ability and HRQoL in
the physical domain did not reach the same levels as in
the early remission group. In particular, HAQ scores
were higher in the randomization arms than in the early
remission group and physical HRQoL did not reach the
levels found in the general population. Although we
found that PROs were associated with achieving remis-
sion and that significantly more patients in arm 2 than
in arm 1 achieved remission at 1 year, we found no sig-
nificant differences in improvement of functional ability
and HRQoL between arms. Only improvement in VASda
was significantly better in arm 2 patients than in arm 1
patients, which can be explained by significantly lower
mean DASs in arm 2 and may also be related to higher
patient expectations associated with earlier introduction
of the subcutaneous TNF inhibitor ADA in this treat-
ment arm [20,21]. Overall, disease activity was well-
suppressed in both arms, which may explain why we
found no differences in improvement in HAQ score and
HRQoL. The actual DAS, rather than having a score just
above or below the threshold of remission, may be the
main determinant of PROs. The patients in the OP sub-
group had results similar to those of patients in arms 1
and 2, which can be explained by the comparable res-
ponse to initial treatment.Conclusion
In patients with early RA, there is an association between
achieving remission and having better functional ability,
HRQoL and other PROs, which may in part be bidirec-
tional. The condition of patients who achieve early remis-
sion improves and remains at levels similar to those of the
general population. This finding supports the idea that
early remission-steered treatment could result in complete
suppression of symptoms with normal functioning and
may prevent chronic deterioration in PROs.Abbreviations
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